{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:28:45Z","timestamp":1793906925980,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03551-1","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:52:41Z","timestamp":1773820361000},"page":"2202-2216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Elexacaftor\/Tezacaftor\/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1706-2382","authenticated-orcid":false,"given":"Jessica Morlando","family":"Geiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna L.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-0672","authenticated-orcid":false,"given":"Carolyn R.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9738-8302","authenticated-orcid":false,"given":"Kate","family":"Van Brunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Dezube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"3551_CR1","doi-asserted-by":"crossref","unstructured":"Cystic Fibrosis Foundation. 2024 cystic fibrosis foundation patient registry highlights. Bethesda, Maryland: Cystic Fibrosis Foundation; 2025. Accessed October 23, 2025. Available from: https:\/\/www.cff.org\/medical-professionals\/2024-patient-registry-highlights.","DOI":"10.1016\/S1569-1993(24)01567-4"},{"key":"3551_CR2","unstructured":"Cystic Fibrosis Foundation. 2024 CF Genetics: The Basics. Accessed October 23, 2025. Available from: https:\/\/www.cff.org\/intro-cf\/cf-genetics-basics."},{"issue":"3","key":"3551_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","volume":"22","author":"EA Cromwell","year":"2023","unstructured":"Cromwell EA, Ostrenga JS, Todd JV, Elbert A, Brown AW, Faro A, et al. Cystic fibrosis prevalence in the United States and participation in the cystic fibrosis foundation patient registry in 2020. J Cyst Fibros. 2023;22(3):436\u201342.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"3551_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.chest.2018.04.036","volume":"154","author":"M Gentzsch","year":"2018","unstructured":"Gentzsch M, Mall MA. Ion channel modulators in cystic fibrosis. Chest. 2018;154(2):383\u201393.","journal-title":"Chest"},{"issue":"3","key":"3551_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.chest.2018.10.006","volume":"155","author":"TG Liou","year":"2019","unstructured":"Liou TG. The clinical biology of cystic fibrosis transmembrane regulator protein: its role and function in extrapulmonary disease. Chest. 2019;155(3):605\u201316.","journal-title":"Chest"},{"issue":"2","key":"3551_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","volume":"22","author":"SJ Schwarzenberg","year":"2023","unstructured":"Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D, et al. Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI. J Cyst Fibros. 2023;22(2):282\u20139.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"3551_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ppul.26243","volume":"58","author":"M Gur","year":"2023","unstructured":"Gur M, Bar-Yoseph R, Hanna M, Abboud D, Keidar Z, Palchan T, et al. Effect of Trikafta on bone density, body composition, and exercise capacity in CF: a pilot study. Pediatr Pulmonol. 2023;58(2):577\u201384.","journal-title":"Pediatr Pulmonol"},{"key":"3551_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.852551","volume":"10","author":"I Korten","year":"2022","unstructured":"Korten I, Kieninger E, Krueger L, Bullo M, Fluck CE, Latzin P, et al. Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study. Front Pediatr. 2022;10:852551.","journal-title":"Front Pediatr"},{"issue":"5","key":"3551_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","volume":"21","author":"S Shakir","year":"2022","unstructured":"Shakir S, Echevarria C, Doe S, Brodlie M, Ward C, Bourke SJ. Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis. J Cyst Fibros. 2022;21(5):807\u201310.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"3551_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jcf.2019.09.008","volume":"18","author":"SMJ Tan","year":"2019","unstructured":"Tan SMJ, Coffey MJ, Ooi CY. Differences in clinical outcomes of paediatric cystic fibrosis patients with and without meconium ileus. J Cyst Fibros. 2019;18(6):857\u201362.","journal-title":"J Cyst Fibros"},{"issue":"4 Pt 1","key":"3551_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0022-3476(05)82478-3","volume":"120","author":"MN Bronstein","year":"1992","unstructured":"Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hambidge KM, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr. 1992;120(4 Pt 1):533\u201340.","journal-title":"J Pediatr"},{"key":"3551_CR12","unstructured":"Cystic Fibrosis Foundation. 2023 Patient Registry Annual Report. 2024. Accessed September 13, 2025. Available from: https:\/\/www.cff.org\/medical-professional\/patient-registry."},{"issue":"6","key":"3551_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1542-3565(04)00169-7","volume":"2","author":"X Dray","year":"2004","unstructured":"Dray X, Bienvenu T, Desmazes-Dufeu N, Dusser D, Marteau P, Hubert D. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol. 2004;2(6):498\u2013503.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3551_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40620-015-0179-z","volume":"28","author":"MJ Wilcock","year":"2015","unstructured":"Wilcock MJ, Ruddick A, Gyi KM, Hodson ME. Renal diseases in adults with cystic fibrosis: a 40 year single centre experience. J Nephrol. 2015;28(5):585\u201391.","journal-title":"J Nephrol"},{"issue":"6","key":"3551_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00467-013-2712-4","volume":"29","author":"E Scurati-Manzoni","year":"2014","unstructured":"Scurati-Manzoni E, Fossali EF, Agostoni C, Riva E, Simonetti GD, Zanolari-Calderari M, et al. Electrolyte abnormalities in cystic fibrosis: systematic review of the literature. Pediatr Nephrol. 2014;29(6):1015\u201323.","journal-title":"Pediatr Nephrol"},{"key":"3551_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/CEOR.S162021","volume":"10","author":"M Hassan","year":"2018","unstructured":"Hassan M, Bonafede MM, Limone BL, Hodgkins P, Sawicki GS. The burden of cystic fibrosis in the Medicaid population. Clinicoecon Outcomes Res. 2018;10:423\u201331.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9","key":"3551_CR17","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1002\/ppul.25535","volume":"56","author":"T Thorat","year":"2021","unstructured":"Thorat T, McGarry LJ, Bonafede MM, Limone BL, Rubin JL, Jariwala-Parikh K, et al. Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatr Pulmonol. 2021;56(9):2833\u201344.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"3551_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jcf.2021.03.025","volume":"21","author":"I Durieu","year":"2022","unstructured":"Durieu I, Dalon F, Reynaud Q, Lemonnier L, Dehillotte C, Berard M, et al. Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis. J Cyst Fibros. 2022;21(1):88\u201395.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"3551_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/03007995.2016.1277196","volume":"33","author":"JL Rubin","year":"2017","unstructured":"Rubin JL, Thayer S, Watkins A, Wagener JS, Hodgkins PS, Schechter MS. Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States. Curr Med Res Opin. 2017;33(4):667\u201374.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"3551_CR20","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/ppul.24178","volume":"53","author":"SD Grosse","year":"2018","unstructured":"Grosse SD, Do TQN, Vu M, Feng LB, Berry JG, Sawicki GS. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010\u20132016. Pediatr Pulmonol. 2018;53(12):1611\u20138.","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"3551_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jval.2012.12.003","volume":"16","author":"K van Gool","year":"2013","unstructured":"van Gool K, Norman R, Delatycki MB, Hall J, Massie J. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health. 2013;16(2):345\u201355.","journal-title":"Value Health"},{"issue":"2","key":"3551_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","volume":"17","author":"V Sergeev","year":"2020","unstructured":"Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Ann Am Thorac Soc. 2020;17(2):147\u201354.","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"3551_CR23","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/ppul.26078","volume":"57","author":"AJ Causer","year":"2022","unstructured":"Causer AJ, Shute JK, Cummings MH, Shepherd AI, Wallbanks SR, Pulsford RM, et al. Elexacaftor-tezacaftor-ivacaftor improves exercise capacity in adolescents with cystic fibrosis. Pediatr Pulmonol. 2022;57(11):2652\u20138.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"3551_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65\u2013124.","journal-title":"Lancet Respir Med"},{"issue":"17","key":"3551_CR25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612\u201320.","journal-title":"N Engl J Med"},{"issue":"44","key":"3551_CR26","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3551_CR27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","volume":"20","author":"ET Zemanick","year":"2021","unstructured":"Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, et al. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the CHEC-SC study. J Cyst Fibros. 2021;20(6):965\u201371.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"3551_CR28","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0112-2021","volume":"17","author":"DH Tewkesbury","year":"2021","unstructured":"Tewkesbury DH, Robey RC, Barry PJ. Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy. Breathe (Sheff). 2021;17(4):210112.","journal-title":"Breathe (Sheff)"},{"key":"3551_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2019;10:1662.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3551_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153\u201378.","journal-title":"J Cyst Fibros"},{"key":"3551_CR31","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","volume":"181S","author":"PM Farrell","year":"2017","unstructured":"Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4-S15 e1.","journal-title":"J Pediatr"},{"key":"3551_CR32","unstructured":"Vertex Pharmaceuticals. Trikafta package insert. Accessed September 13, 2025. Available from: https:\/\/pi.vrtx.com\/files\/uspi_elexacaftor_tezacaftor_ivacaftor.pdf."},{"issue":"19","key":"3551_CR33","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"4","key":"3551_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s41030-023-00241-z","volume":"9","author":"MS Schechter","year":"2023","unstructured":"Schechter MS, Sabater-Anaya N, Oster G, Weycker D, Wu H, Arteaga-Solis E, et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on healthcare resource utilization and associated costs among people with cystic fibrosis in the US: a retrospective claims analysis. Pulm Ther. 2023;9(4):479\u201398.","journal-title":"Pulm Ther"},{"key":"3551_CR35","doi-asserted-by":"crossref","unstructured":"Merlo CA, Romdhani H, Der Sarkssian M, Muthukumar A, McGarry LJ, Lou Y, Brigham MD, Van Brunt K. Clinical outcomes in concurrent elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) treated vs.ineligible cohorts in the US Cystic Fibrosis Foundation Patient Registry (CFFPR) during COVID-19. In: Poster presentation at: 47th European Cystic Fibrosis Conference; June 5\u20138, 2024; Glasgow, United Kingdom.","DOI":"10.1016\/S1569-1993(24)00264-9"},{"issue":"12","key":"3551_CR36","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ppul.23554","volume":"51","author":"JF Levy","year":"2016","unstructured":"Levy JF, Rosenberg MA, Farrell PM. Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis. Pediatr Pulmonol. 2016;51(12):1295\u2013303.","journal-title":"Pediatr Pulmonol"},{"key":"3551_CR37","first-page":"384","volume":"51","author":"W Saunders","year":"2016","unstructured":"Saunders W, Ruban C. One-year prevalence, comorbidities and cost of cystic fibrosis inpatient admissions in the USA. Pediatr Pulmonol. 2016;51:384.","journal-title":"Pediatr Pulmonol"},{"issue":"10212","key":"3551_CR38","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20138.","journal-title":"Lancet"},{"issue":"12","key":"3551_CR39","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, et al. A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203(12):1522\u201332.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"3551_CR40","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1164\/rccm.202502-0512OC","volume":"211","author":"C Wainwright","year":"2025","unstructured":"Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, et al. Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children >\/=6 years with cystic fibrosis and at least one F508del allele: a 192-week, phase 3, open-label extension study. Am J Respir Crit Care Med. 2025;211(10):1915\u201325.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"3551_CR41","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1164\/rccm.202411-2231OC","volume":"211","author":"CL Daines","year":"2025","unstructured":"Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, et al. Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del allele: a phase 3, open-label extension study. Am J Respir Crit Care Med. 2025;211(10):1901\u201314.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"3551_CR42","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamaoto.2023.2701","volume":"149","author":"S Sheikh","year":"2023","unstructured":"Sheikh S, Ho ML, Eisner M, Gushue C, Paul G, Holtzlander M, et al. Elexacaftor-tezacaftor-ivacaftor therapy for chronic sinus disease in cystic fibrosis. JAMA Otolaryngol Head Neck Surg. 2023;149(12):1075\u201382.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"7","key":"3551_CR43","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","volume":"121","author":"J Bailey","year":"2021","unstructured":"Bailey J, Rozga M, McDonald CM, Bowser EK, Farnham K, Mangus M, et al. Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review. J Acad Nutr Diet. 2021;121(7):1364-78 e2.","journal-title":"J Acad Nutr Diet"},{"key":"3551_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/life14101309","author":"M Bassi","year":"2024","unstructured":"Bassi M, Strati MF, Spiandorello G, Scalas M, Cresta F, Calevo MG, et al. One-year effect of elexacaftor\/tezacaftor\/ivacaftor therapy on HbA1c levels and insulin requirement in patients with insulin-dependent cystic fibrosis-related diabetes: a retrospective observational study. Life. 2024. https:\/\/doi.org\/10.3390\/life14101309.","journal-title":"Life"},{"key":"3551_CR45","doi-asserted-by":"crossref","unstructured":"Dasenbrook E. Keep cystic fibrosis patients out of the hospital. Cleve Clin J Med 2020.","DOI":"10.3949\/ccjm.87a.ccc005"},{"key":"3551_CR46","unstructured":"Cystic Fobrosis Foundation. Patient Registry 2020 Annual Data Report. 2020. Accessed September 13, 2025. Available from: https:\/\/www.cff.org\/medical-professional\/patient-registry."},{"issue":"5","key":"3551_CR47","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/ppul.25250","volume":"56","author":"S Patel","year":"2021","unstructured":"Patel S, Thompson MD, Slaven JE, Sanders DB, Ren CL. Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic. Pediatr Pulmonol. 2021;56(5):1271\u20133.","journal-title":"Pediatr Pulmonol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03551-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03551-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03551-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:37:32Z","timestamp":1778229452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03551-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3551"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03551-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jessica Morlando Geiger, Mark Jennings, Chen Mo, and Kate Van Brunt are employees of Vertex Pharmaceuticals Incorporated and may own stock or stock options in that company. Brenna L. Brady And Carolyn R. Lew are employees of Merative who received funding from Vertex to conduct this study. Rebecca Dezube reports consulting fees from Vertex Pharmaceuticals Incorporated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All database records are de-identified and fully compliant with United States patient confidentiality requirements, including the Health Insurance Portability and Accountability Act (HIPAA) of 1996. As all database records are de-identified and certified to be in compliance with the conditions set forth in Sects.\u00a0164.514 (a)-(b)1ii of the HIPAA privacy rule, this study was determined to be exempt from Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}